BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tu JF, Ding YH, Chen L, Ying XH, Zhang DK, Wu FZ, Zhao ZW, Ji JS, Zhang WG, Zou H. Iodine-125 Brachytherapy Prophylaxis after Radiofrequency Ablation Cannot Benefit Patients in High Risk of Locoregional Hepatocellular Carcinoma Recurrence. Sci Rep 2017;7:3689. [PMID: 28623296 DOI: 10.1038/s41598-017-03831-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Wei S, Li C, Li M, Xiong Y, Jiang Y, Sun H, Qiu B, Lin CJ, Wang J. Radioactive Iodine-125 in Tumor Therapy: Advances and Future Directions. Front Oncol 2021;11:717180. [PMID: 34660280 DOI: 10.3389/fonc.2021.717180] [Reference Citation Analysis]
2 Ren Y, Dong X, Chen L, Sun T, Alwalid O, Kan X, Su Y, Xiong B, Liang H, Zheng C, Han P. Combined Ultrasound and CT-Guided Iodine-125 Seeds Implantation for Treatment of Residual Hepatocellular Carcinoma Located at Complex Sites After Transcatheter Arterial Chemoembolization. Front Oncol 2021;11:582544. [PMID: 33738247 DOI: 10.3389/fonc.2021.582544] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Schullian P, Putzer D, Laimer G, Levy E, Bale R. Feasibility, safety, and long-term efficacy of stereotactic radiofrequency ablation for tumors adjacent to the diaphragm in the hepatic dome: a case-control study. Eur Radiol 2020;30:950-60. [PMID: 31489472 DOI: 10.1007/s00330-019-06399-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]